ClinicalTrials.Veeva

Menu

Evaluation of the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula (Leopard)

Nutricia logo

Nutricia

Status

Completed

Conditions

Regurgitation, Gastric

Treatments

Other: Anti-regurgitation infant formula

Study type

Interventional

Funder types

Industry

Identifiers

NCT03371615
EBB16GL10424

Details and patient eligibility

About

A randomised, controlled, double-blind trial to evaluate the tolerance and safety of a new partly fermented anti-regurgitation infant formula containing prebiotics and locust bean gum in infants with regurgitation.

Enrollment

182 patients

Sex

All

Ages

3 to 13 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Singleton healthy term infant aged 3 - 13 weeks;

  2. Gestational age at birth 37- 42 weeks;

  3. Normal birth weight for gestational age and gender i.e. 10th to 90th percentile compared to the WHO or local growth charts;

  4. Infants with regurgitation that are otherwise healthy, based upon the following criteria: 1) Regurgitation of 2 or more times per day for 1 or more weeks according to reported history, 2) an indication for the use of AR formula according to the investigator at screening/randomisation.

  5. Fully formula fed for at least 7 days before screening/randomisation;

  6. Written informed consent from the parent(s) and/or legally acceptable representative(s), aged ≥ 18 years.

Exclusion criteria

    1. History of retching, hematemesis, aspiration, apnoea, failure to thrive, feeding or swallowing difficulties or abnormal posturing; 2. Gastrointestinal infection within 4 weeks prior to randomisation; 3. Congenital condition and/or previous or current illness and (or) medication use that could interfere with the main study outcomes according to the investigator; 4. Known cow's milk protein allergy, lactose intolerance, or galactosaemia including history of any other allergic manifestations or known allergy to any of the study product ingredients (especially scGOS); 5. Presence of any other gastrointestinal symptom(s)/disorder(s) that are not functional in nature, as assessed by the investigator's clinical judgement; 6. Received any of the following products/medication prior to randomisation: systemic antibiotics, prokinetics, proton pump inhibitors, complementary feeding/weaning within 4 weeks prior to randomisation; 7. Incapability of the parent(s) to comply with the study protocol or investigator's uncertainty about the willingness or ability of the parent(s) to comply with the protocol requirements; 8. Current participation in another clinical intervention study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

182 participants in 2 patient groups, including a placebo group

Fermented IF + LBG + Gos Fos
Active Comparator group
Description:
Fermented infant formula with Locust bean gum and Gos Fos
Treatment:
Other: Anti-regurgitation infant formula
Fermented IF +LBG
Placebo Comparator group
Description:
Fermented infant formula with Locust bean gum
Treatment:
Other: Anti-regurgitation infant formula

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems